EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Real‐World Clinical Experience With Sodium Phenylbutyrate and Taurursodiol at a Single Amyotrophic Lateral Sclerosis Center in the United States

Narghes Calcagno iD, Erica Scirocco iD, Erin Clampffer, Grace Addy, Sean Morgan, Neel Parikh, Dylan V Neel iD, Jennifer Scalia, Rebekah Young, Matteo Locatelli, deMauri S Mackie iD, James D Berry iD und 1 weitere

European Journal of Neurology · 2025-09 · 32 (9)

DOI: 10.1111/ene.70360 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Neurology, online erschienen am 18.09.2025. Verfasst von Narghes Calcagno und 12 weiteren Autor:innen. Beteiligte Einrichtung: Sean M. Healey and AMG Center for ALS and the Neurological Clinical Research Institute, Massachusetts General Hospital, Harvard Medical School, Bosto…. Hauptthemen laut MEDLINE: Amyotrophic Lateral Sclerosis, Phenylbutyrates. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Amylyx Pharmaceuticals Inc.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction/Aims Sodium phenylbutyrate ( PB ) and taurursodiol ( TURSO )— PB and TURSO —was approved as a treatment for amyotrophic lateral sclerosis ( ALS ) in the United States in 2022 based on the results of a phase 2 trial, but was voluntarily withdrawn from the market in 2024 after negative results from its phase 3 trial. The objective of our study was to describe the real‐world clinical experience with PB and TURSO at one ALS clinic.

Methods

This was a retrospective chart review of all ALS patients receiving a PB and TURSO prescription at the Massachusetts General Hospital ALS Clinic between October 1, 2022, and September 30, 2023. Data were extracted from patients' electronical medical records up to December 31, 2023.

Results

A total of 441 ALS patients received a PB and TURSO prescription, with 329 (75%) initiating the medication. The average length of treatment was 285 days, and the rate of drug discontinuation during the study period was 41% (N=135). The most common reason for drug discontinuation was side effects (N=93, 69%), with the most common being gastrointestinal issues (N=69). No hospitalizations, deaths, or serious adverse events were considered related to treatment with PB and TURSO.

Discussion

Experience in real‐world clinical settings can help supplement trial data with information on the drug performance at various stages of disease progression. Adverse events impacted treatment persistence in routine clinical practice, underscoring the need for vigilant monitoring and tailored supportive interventions to optimize treatment adherence.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Amyotrophic Lateral SclerosisPhenylbutyratesHumansMaleFemaleRetrospective StudiesMiddle AgedAgedUnited StatesAdult

Stichwörter der Autor:innen

PB TURSOamyotrophic lateral sclerosisdrug safety profileinsurance constraintsreal‐word experience

Substanzen

Phenylbutyrates4-phenylbutyric acidsodium phenylbutyrate and taurursodiol

Autor:innen und Institutionen

  • Sean M. Healey and AMG Center for ALS and the Neurological Clinical Research Institute, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Neurology and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milan, Italy.
  • Amylyx Pharmaceuticals, Inc., Cambridge, Massachusetts, USA.
  • Spaulding Rehabilitation Hospital, Harvard Medical School, Boston, Massachusetts, USA.

ORCID-Profile: Narghes Calcagno, Erica Scirocco, Dylan V Neel, deMauri S Mackie, James D Berry, Sabrina Paganoni

Förderung

  • Amylyx Pharmaceuticals Inc

Zitieren

APA

Calcagno, N., Scirocco, E., Clampffer, E., Addy, G., Morgan, S., Parikh, N., Neel, D. V., Scalia, J., Young, R., Locatelli, M., Mackie, D. S., Berry, J. D., & Paganoni, S. (2025). Real‐World Clinical Experience With Sodium Phenylbutyrate and Taurursodiol at a Single Amyotrophic Lateral Sclerosis Center in the United States. European Journal of Neurology, 32(9). https://doi.org/10.1111/ene.70360

Vancouver

Calcagno N, Scirocco E, Clampffer E, Addy G, Morgan S, Parikh N, et al. Real‐World Clinical Experience With Sodium Phenylbutyrate and Taurursodiol at a Single Amyotrophic Lateral Sclerosis Center in the United States. European Journal of Neurology. 2025;32(9). doi:10.1111/ene.70360

BibTeX
@article{Calcagno2025,
  author = {Calcagno, Narghes and Scirocco, Erica and Clampffer, Erin and Addy, Grace and Morgan, Sean and Parikh, Neel and Neel, Dylan V and Scalia, Jennifer and Young, Rebekah and Locatelli, Matteo and Mackie, deMauri S and Berry, James D and Paganoni, Sabrina},
  title = {Real‐World Clinical Experience With Sodium Phenylbutyrate and Taurursodiol at a Single Amyotrophic Lateral Sclerosis Center in the United States},
  journal = {European Journal of Neurology},
  year = {2025},
  volume = {32},
  number = {9},
  doi = {10.1111/ene.70360}
}
Kostenlos starten →